 Novocure will win a 10 of its targeted lung cancer market, an analyst predicted Tuesday as he examined NVCR stocks double-digit drop. The post Novocure Has Fallen More Than 20 Over Seven Days Why It Fell From Grace appeared first on Investors Business Daily. 